Dietary Supplement Legal Update - June 2017

June 13, 2017

Editors: Kevin M. Bell and Richard J. Oparil

The dietary supplement industry continues to confront legal and regulatory challenges. For additional information, contact Kevin Bell or Richard Oparil of Porzio's Washington, D.C. office.

The recent significant developments in this *Dietary Supplement Legal Update* issue include:

- Senate Confirms FDA Commissioner
- Supreme Court Limits Where Patent Infringement Cases May Be Brought
- Supreme Court to Consider Whether Patent Office Proceedings to Review the Validity of Patents is Constitutional
- Oregon AG Settles Dispute with Vitamin Shoppe
- FDA is Posting Adverse Event Reports Online
- FDA Issues Warning Letter for Drug Claims
- FDA Issues 14 Warning Letters to 14 Companies Selling Cancer Treatment Products
- FDA Warning Letter on CBD Product
- Eleventh Circuit Rules on First Amendment Labelling Issue
- FTC Reminds Influencers and Brands to Clearly Disclose Relationship in Social Media Endorsements
- Guilty Plea in DMAA Case
- Hi-Tech Loses Defamation Case Against Harvard Researcher
- Official Clarifies that the FTC Does Not Require Two Clinical Trials for Claim Substantiation

To read the full issue, please click here.